#India #Mumbai #CDMO #Piramal Pharma #Nitrosamine

Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities

Piramal Pharma Solutions, a premier contract development and manufacturing organization (CDMO), has successfully navigated the regulatory landscape to ensure its product safety and compliance with evolving guidelines concerning nitrosamine impurities. This achievement, announced recently, reaffirms the company's commitment to patient safety and operational excellence.

Understanding Nitrosamines

Nitrosamines have gained attention due to their potential carcinogenic properties, often emerging as unintended byproducts in certain medications. As international standards regarding nitrosamine-related impurities have markedly changed over the years, pharmaceutical manufacturers, including Piramal, have faced the challenge of adapting operations to meet these stringent requirements.

Proactive Action Plan

To address these requirements, Piramal Pharma Solutions developed a robust action plan consisting of multiple strategic steps. A core team consisting of experts from various sectors, including Regulatory Affairs, Quality Control, Research and Development, and Manufacturing, was established to steer these efforts. This collaboration ensured that regulatory guidelines were diligently followed and adapted as new information was released.

One of the critical components of this initiative was the creation and continuous updating of the Position Paper, which served as a centralized document providing guidance regarding regulatory expectations. This paper outlined roles and responsibilities across the organization, facilitating an effective response to the new requirements.

Risk Assessment and Testing

Central to Piramal's path to compliance was the emphasis on risk assessments for all drug substances and products concerned with nitrosamines. Each identified product underwent confirmatory testing, and where necessary, control measures were enacted to minimize safety risks. Currently, all commercial products from Piramal Pharma Limited comply with prevailing international regulations, with new batches scheduled for production only post regulatory clearances.

The enhancement of in-house testing capabilities was another significant aspect of the compliance journey. By investing in state-of-the-art equipment and upgrading facilities in Ahmedabad and Digwal, Piramal aims to streamline the testing process and mitigate potential drug shortages arising from impurity issues.

Commitment to Patient Safety

Rashida Najmi, Chief Quality Officer at Piramal Pharma Limited, emphasized that patient well-being remains their top priority. The recent accomplishment in adhering to regulatory demands for nitrosamine impurities underscores this commitment. Najmi affirmed that with the proactive measures and improved capabilities, Piramal is wellprepared to navigate the evolving landscape of nitrosamine regulations while upholding the highest safety and quality standards.

Future Steps

As the regulatory environment regarding nitrosamines continues to evolve, Piramal Pharma Solutions stands firm in its dedication to patient safety and operational integrity. The company plans to support its partners in adapting to the complexities of nitrosamine control. This dedication will be realized through transparent communication, continuous improvement practices, and the maintenance of the highest pharmaceutical quality standards.

About Piramal Pharma Solutions

Piramal Pharma Solutions offers comprehensive development and manufacturing services across the drug lifecycle. Operating a globally integrated network of facilities in North America, Europe, and Asia, the company delivers a broad array of services, from drug discovery to commercial supply of APIs and finished dosage forms. The firm also specializes in services for biologics, including vaccines and gene therapies, in collaboration with its associate company, Yapan Bio Private Limited.

For more information on Piramal Pharma Solutions and their services, visit their official website.

Conclusion

Piramal Pharma Solutions has demonstrated leadership in the pharmaceutical industry by adhering to stringent regulatory requirements and placing patient safety at the forefront. With these achievements, the company not only reinforces its reputation but also sets a benchmark for compliance in the industry.